Santaris Adds miR-33 to Its Pipeline Via Mass General Licensing Deal | GenomeWeb

By Doug Macron

Santaris Pharma unveiled its newest microRNA therapeutic program this week having acquired intellectual property from Massachusetts General Hospital related to the use of miR-33 as a target for cardiovascular disorders including hypercholesterolemia.

In doing so, Santaris has expanded its stable of cardiovascular drug candidates based on its proprietary locked nucleic acid technology and added the second miRNA-inhibiting compound to its pipeline.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.